论文部分内容阅读
环孢素A(Cyclosporine A,CyA)是一种新型强效免疫抑制剂,能降低排斥反应发生率和严重程度,显著提高移植病人的存活率,已广泛应用于器官移植、骨髓移植、自身免疫性疾病和难治性皮肤病的治疗。目前国内市场上流通环孢索A的二种剂型:胶囊剂型(Sandimnlum,山地明)和微乳剂型(Sandimmune Neoral,新山地明)。现就2种剂型在吸收、药动学参数、生物利用度、安全性、忍受性、变异性等方面作了比较,从而
Cyclosporine A (CyA) is a potent and potent immunosuppressive agent that can reduce the incidence and severity of rejection and significantly improve the survival rate of transplant patients. It has been widely used in organ transplantation, bone marrow transplantation, autoimmunity Treatment of sexual and refractory skin conditions. There are currently two dosage forms of cyclosporin A circulating in the domestic market: Sandimnlum (Liming Ming) and Sandimmune Neoral (Shinseki Ming). Now on the two formulations in the absorption, pharmacokinetic parameters, bioavailability, safety, endurance, variability and other aspects are compared to